Clinical Trial

Clinical Study on the Safety and Efficacy of Human Amniotic Mesenchymal Stem Cells in the Treatment of Premature Ovarian Insufficiency

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Record status
This record was last updated August 11, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
There is a high incidence of women suffering from Primary Ovarian Insufficiency (POI). So far, there was no treatment sufficient enough to cure POI. Cell therapy is a rapidly developing field and have shown immense promise in the treatment of ovarian dysfunction. In this study, the investigator will evaluate the safety of human Amniotic mesenchymal stem cells (hA-MSCs) therapy in women suffering from POI.
Trial Details
NCT Number NCT07115082
Lead Sponsor Yan Hongli
Conditions Premature Ovarian Insufficiency
Enrollment 50 participants
Start Date 2024-10-15
Primary Completion 2025-12 (estimated)
Study Completion 2026-03-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-11